Resources
Newsletters - News and Events - Scientific Bibliography - Glossary - Nanotechnology Related Links Nanoparticle Immunotoxicity WorkshopWorkshop |
Time | Presentation Title | Speaker |
8.00 - 8.10 a.m. | Welcome and Introductions | Scott McNeil, Ph.D. Director, Nanotechnology Characterization Lab., SAIC/NCI-Frederick |
8.10 - 8.40 a.m. | Analysis of complement activation: points to consider during preclinical development | Carolina Salvador Morales, Ph.D. Brigham and Women’s hospital/ Harvard Medical School/MIT |
8.50 - 9.20 a.m. | In vivo models to study nanoparticle-mediated complement activation | Hila Epstein-Barash, Ph.D. MIT |
9.30 - 10.00 a.m. | Analysis of nanoparticle effects on platelets | Jan Simak, Ph.D. US FDA |
Break | ||
10.20 - 10.50 a.m. | Challenges with using LAL assay to analyze endotoxin contamination of nanomaterials | Marina Dobrovolskaia, Ph.D. Nanotechnology Characterization Lab., SAIC/NCI-Frederick Inc. |
11.00 - 11.30 a.m. | Development of alternative, cytokine-based, method for analysis of nanoparticle contamination with bacterial endotoxin | Marina Zaitseva, Ph.D. US FDA |
11.40 a.m. - 12.10 p.m. | Analysis of nanoparticle interaction with erythrocytes | Barry Neun, B.S. Nanotechnology Characterization Lab., SAIC-Frederick Inc. |
Lunch | ||
1.20 - 1.50 p.m. | Approaches to analyze nanoparticle uptake by the immune cells | Parag Aggarwal, Ph.D. Nanotechnology Characterization Lab., SAIC-Frederick Inc. |
2.00 - 2.30 p.m. | In vivo models to study nanoparticles’ potential to cause hypersensitivity reactions: focus on LLNA assay | David Warheit, Ph.D. DuPont |
2.40 – 3.10 p.m. | In vivo models to study nanoparticle-mediated immunotoxicity | Dori Germolec, Ph.D. NTP/NIEHS |
3.20 - 3.50 p.m. | Drugs, nanoparticles and regulations – a complex mixture | James Weaver, Ph.D. US FDA |
Break | ||
4.10 – 5.00 p.m. | Concluding discussions | All |
A Service of the National Cancer Institute |